

Clerk of the House of Representatives  
 Legislative Resource Center  
 B-106 Cannon Building  
 Washington, DC 20515

Secretary of the Senate  
 Office of Public Records  
 232 Hart Building  
 Washington, DC 20510

RECEIVED  
 OFFICE OF THE SENATE  
 PUBLIC RECORDS

FEB 14 PM 4:48

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <b>The Duherstein Group, Inc.</b>			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address <b>2100 Pennsylvania Ave, NW Ste 500</b> City <b>Washington</b> State/Zip (or Country) <b>DC 20037 USA</b>			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name <b>John W. Angus, III</b>	Telephone <b>202-728-1100</b>	E-mail (optional)	5. Senate ID # <b>12675-253</b>
7. Client Name <input type="checkbox"/> Self <b>Pharmacia Corporation</b>	6. House ID # <b>31841024</b>		

**TYPE OF REPORT** 8. Year 2000 Midyear (January 1-June 30)  **OR** Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  >> Termination Date \_\_\_\_\_

11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p><b>12. Lobbying Firms</b></p> <p><b>INCOME</b> relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> &gt;&gt; \$ <u>520,000.00</u>  <small>Income (nearest \$20,000)</small></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p><b>EXPENSES</b> relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> &gt;&gt; \$ _____  <small>Expenses (nearest \$20,000)</small></p> <p><b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature  Date 02/14/2001

Printed Name and Title John W. Angus, III - Senior Vice President & GC Page 1 of 4

Registrant Name: The Duberstein Group, Inc.

Client Name: Pharmacia Corporation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

**H.R.1109, Medicare Outpatient Prescription Drug Coverage Act of 1999, Medicare prescription drug benefit**  
**H.R.1495, Access to Prescription Medications in Medicare Act of 1999, Medicare prescription drug benefit**  
**H.R.2012, Medicare Prescription Drug Benefit Act of 1999, Medicare prescription drug benefit**  
**H.R.3665, Prescription Price Equity Act of 2000, Medicare prescription drug benefit**  
**H.R.4577, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2001, Medicare prescription drug benefit**  
**H.R.4680, Medicare Rx 2000 Act, Medicare prescription drug benefit**  
**H.R.664, Prescription Drug Fairness for Seniors Act of 1999, Medicare prescription drug benefit**  
**S.2553, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2001, Medicare prescription drug benefit**  
**S.2753, Medicare Expansion for Needed Drugs (MEND) Act of 2000, Medicare prescription drug benefit**

17. House(s) of Congress and Federal agencies contacted  Check if None

House of Representatives  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Angus, III, John W.		No
Berman, Michael S.		No
Champlin, Steven M.		No
Duberstein, Kenneth M.		No
Gandy, Henry M.		No
Meyer, Daniel		No

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date 02/14/2001

Printed Name and Title John W. Angus, III - Senior Vice President & GC Page 2 of 4

Registrant Name: The Duberstein Group, Inc.

Client Name: Pharmacia Corporation

Item	Description	Data
16	Lobbying issues	S.731, Prescription Drug Fairness for Seniors Act of 1999, Medicare prescription drug benefit
16	Lobbying issues	S.841, Access to Rx Medications in Medicare Act of 1999, Medicare prescription drug benefit
16	Lobbying issues	
16	Lobbying issues	

Registrant Name: The Duberstein Group, Inc.

Client Name: Pharmacia Corporation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific Lobbying issues

**H.R.3240, Drug Import Fairness Act of 1999, Prices of prescription drugs abroad**

**H.R.4461, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2001, Reimportation of prescription drugs**

**S.2464, Prescription Drug Fairness Act, Prices of prescription drugs abroad**

**S.2465, Prescription Price Equity Act of 2000, Prices of prescription drugs abroad**

**S.2466, To require the United States Trade Representative to enter into negotiations to eliminate price controls imposed by certain foreign countries on prescription drugs, Prices of prescription drugs abroad**

17. House(s) of Congress and Federal agencies contacted  Check if None

**House of Representatives**

**Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<b>Angus, III, John W.</b>		No
<b>Berman, Michael S.</b>		No
<b>Champlin, Steven M.</b>		No
<b>Duberstein, Kenneth M.</b>		No
<b>Gandy, Henry M.</b>		No
<b>Meyer, Daniel</b>		No

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date 02/14/2001

Printed Name and Title John W. Angus, III - Senior Vice President & GC Page 4 of 4